FDA and Manufacturers Intensify Concerns about Data Integrity

被引：0

|

作者：

Wechsler, Jill

机构：

来源：

BIOPHARM INTERNATIONAL | 2016年 / 29卷 / 07期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：8 / 9

页数：2

相关论文

共 50 条

[21] Combining efficiency and concerns about integrity when using human biobanks
Hansson, Mats G.
STUDIES IN HISTORY AND PHILOSOPHY OF SCIENCE PART C-STUDIES IN HISTORY AND PHILOSOPHY OF BIOLOGICAL AND BIOMEDIAL SCIENCES, 2006, 37 (03): : 520 - 532
[22] US FDA has concerns about safety of compounded ketamine nasal spray
Reactions Weekly, 2022, 1895 (1) : 3 - 3
[23] FDA Releases Guidance on Biosimilars, Therapeutic Proteins, and Data Integrity
不详
BIOPHARM INTERNATIONAL, 2016, 29 (05) : 8 - 8
[24] What's New with the FDA's Data Integrity Guidance?
McDowall, R. D.
SPECTROSCOPY, 2016, 31 (09) : 22 - 29
[25] Concerns about modelling of the EDGES data Reply
Bowman, Judd D.
Rogers, Alan E. E.
Monsalve, Raul A.
Mozdzen, Thomas J.
Mahesh, Nivedita
NATURE, 2018, 564 (7736) : E35 - E35
[26] MANUFACTURERS VIEW OF PRODUCT INTEGRITY
GADSDEN, HW
FOOD DRUG COSMETIC LAW JOURNAL, 1972, 27 (01): : 34 - 39
[27] Concerns about pathology expertise and data quality
McInnes, Elizabeth F.
Meyerholz, David K.
Arends, Mark J.
JOURNAL OF PATHOLOGY, 2023, 259 (04): : 468 - 468
[28] Opioid Regulation Challenges FDA and Manufacturers
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2013, 26 (12) : 12 - 13
[29] FDA and Manufacturers Ponder Biosimilars Pathway
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2011, 24 (07) : 12 - 14
[30] FDA Issues Updates for Device Manufacturers
Journal of Validation Technology, 2021, 27 (05) : 1 - 2

← 1 2 3 4 5 →